Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. That said, here are three value stocks facing an uphill battle and some other investments you should look into instead.

Himax (HIMX)

Forward P/E ratio: 13.9x

Taiwan-based Himax Technologies (NASDAQ: HIMX) is a leading manufacturer of display driver chips and timing controllers used in TVs, laptops, and mobile phones.

Why Do We Think HIMX Will Underperform?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 7% annually over the last five years
2. Free cash flow margin shrank by 16.3 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
3. 6× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly

Himax’s stock price of $11.95 implies a valuation ratio of 13.9x forward P/E. Dive into our free research report to see why there are better opportunities than HIMX.

Campbell's (CPB)

Forward P/E ratio: 12.2x

With its iconic canned soup as its cornerstone product, Campbell's (NASDAQ: CPB) is a packaged food company with an illustrious portfolio of brands.

Why Do We Avoid CPB?

1. Declining unit sales over the past two years show it’s struggled to move its products and had to rely on price increases
2. Estimated sales decline of 2.9% for the next 12 months implies a challenging demand environment
3. Earnings per share fell by 10.2% annually over the last three years while its revenue grew, showing its incremental sales were much less profitable

At $20.59 per share, Campbell's trades at 12.2x forward P/E. To fully understand why you should be careful with CPB, check out our full research report (it’s free).

Phibro Animal Health (PAHC)

Forward P/E ratio: 11x

With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.

Why Do We Think Twice About PAHC?

1. Subscale operations are evident in its revenue base of $1.52 billion, meaning it has fewer distribution channels than its larger rivals
2. Estimated sales growth of 3.6% for the next 12 months implies demand will slow from its two-year trend
3. Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 0.9% for the last five years

Phibro Animal Health is trading at $38.08 per share, or 11x forward P/E. Read our free research report to see why you should think twice about including PAHC in your portfolio.

Stocks we like more

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.